Xiaoteng Liu
Tianjin Medical University
6 Papers
25 Citations
Xiaoteng Liu is an academic researcher from Tianjin Medical University. The author has contributed to research in topics: Bladder cancer & Carcinoma in situ. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
The evaluation of the association between the metabolic syndrome and tumor grade and stage of bladder cancer in a Chinese population.
Nan Sha,Hao Xu,Tao Chen,Dawei Tian,Wanqin Xie,Linguo Xie,Yu Zhang,Chen Xing,Xiaoteng Liu,Zhonghua Shen,Zhouliang Wu,Hailong Hu,Changli Wu +12 more
TL;DR: The patients with MetS in the People’s Republic of China were found to have statistically significant higher T stage and grade of bladder cancer.
Impact of squamous and/or glandular differentiation on recurrence and progression following transurethral resection for non‑muscle invasive urothelial carcinoma of bladder
Hao Xu,Linguo Xie,Xiaoteng Liu,Yu Zhang,Zhonghua Shen,Tao Chen,Xiaoyu Qiu,Nan Sha,Chen Xing,Zhouliang Wu,Hailong Hu,Changli Wu +11 more
TL;DR: The presence of squamous and/or glandular differentiation was associated with a higher recurrence rate and shorter RFS time in patients with NMIUCB and is therefore an independent prognostic predictor of recurrence.
Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective study.
Yu Zhang,Linguo Xie,Tao Chen,Wanqin Xie,Zhouliang Wu,Hao Xu,Chen Xing,Nan Sha,Zhonghua Shen,Yungkai Qie,Xiaoteng Liu,Hailong Hu,Changli Wu +12 more
TL;DR: Intravenous chemotherapy combined with intravesical chemotherapy offers a better oncologic outcome than the intravesicals chemotherapy alone for patients with T1G3 bladder urothelial carcinoma after TURBT, and it may be considered as a new therapy strategy for T1g3 bladder cancer.
8
Risk Factors Predictive of Recurrence and Progression for Patients Who Suffered Initial Recurrence After Transurethral Resection of Stage pT1 Bladder Tumor in Chinese Population: A Retrospective Study
Zhonghua Shen,Linguo Xie,Tao Chen,Dawei Tian,Xiaoteng Liu,Hao Xu,Yu Zhang,Zhouliang Wu,Nan Sha,Chen Xing,Na Ding,Hailong Hu,Chang-Li Wu +12 more
TL;DR: Several risk factors relevant to RFS and PFS for patients who have had a history of recurrence of pT1 bladder tumor after TUR are identified, which may help urologists to stratify patients into distinct risk groups ofRecurrence and progression, which probably contributes to the individualized treatment for patients.
Impact of lymphovascular invasion on recurrence and progression rates in patients with pT1 urothelial carcinoma of bladder after transurethral resection.
Nan Sha,Linguo Xie,Tao Chen,Chen Xing,Xiaoteng Liu,Yu Zhang,Zhonghua Shen,Hao Xu,Zhouliang Wu,Hailong Hu,Changli Wu +10 more
TL;DR: The presence of LVI in transurethral resection of bladder tumor specimens is significantly associated with higher recurrence rate and shorter RFS time in patients with newly diagnosed T1 urothelial carcinoma of the bladder, and is an independent prognostic predictor for disease recurrence.